AMICUS THERAPEUTICS, INC. Quarterly Depreciation, Depletion and Amortization in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
Amicus Therapeutics, Inc. quarterly/annual Depreciation, Depletion and Amortization history and growth rate from Q2 2018 to Q3 2024.
  • Amicus Therapeutics, Inc. Depreciation, Depletion and Amortization for the quarter ending September 30, 2024 was $2.17M, a 2.6% decline year-over-year.
  • Amicus Therapeutics, Inc. Depreciation, Depletion and Amortization for the twelve months ending September 30, 2024 was $8.69M, a 24.1% increase year-over-year.
  • Amicus Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2023 was $7.87M, a 47.4% increase from 2022.
  • Amicus Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2022 was $5.34M, a 14% decline from 2021.
  • Amicus Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2021 was $6.21M, a 29.8% decline from 2020.
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $8.69M $2.17M -$58K -2.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $8.75M $2.18M -$24K -1.09% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $8.77M $2.15M +$897K +71.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $7.87M $2.18M +$871K +66.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $7M $2.23M +$942K +73.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $6.06M $2.21M +$872K +65.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $5.19M $1.26M -$154K -10.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $5.34M $1.31M -$207K -13.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $5.55M $1.29M -$234K -15.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $5.78M $1.33M -$233K -14.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $6.02M $1.41M -$193K -12% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $6.21M $1.52M -$1.03M -40.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $7.24M $1.52M -$976K -39.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $8.21M $1.57M -$472K -23.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $8.69M $1.6M -$160K -9.07% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $8.85M $2.55M +$1.03M +68.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $7.81M $2.5M +$1.38M +124% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $6.43M $2.04M +$885K +76.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $5.55M $1.76M +$773K +78% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $4.78M $1.51M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $1.12M +$43K +4.01% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.15M +$181K +18.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $991K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q3 2018 $1.07M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $973K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.